Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoMed Pharmaceuticals has initiated OMP-59R5 Phase 1 clinical trial and has dosed first patient with advanced solid tumor cancers.
Subscribe to our email newsletter
The company has also dosed first patient in the trial.
The trial is designed to investigate the safety and escalating doses of OMP-59R5 in patients who have received prior treatment with standard chemotherapeutics.
The Phase 1 trial also evaluates the pharmacokinetics, biomarkers and initial indications of efficacy.
In the previous studies OMP-59R5 has demonstrated decrease in the frequency of tumor-initiating cells across a variety of tumor types.
OncoMed Pharma president and CEO Paul Hastings said that the advancement of the second antibody into the clinic represents an important milestone for OncoMed, demonstrating productive drug discovery capabilities and steady execution on our objectives for the programs.